OBJECTIVE: To evaluate the efficacy and safety of dietary lysine restriction as an adjunct to pyridoxine therapy on biochemical parameters, seizure control, and developmental/cognitive outcomes in children with pyridoxine-dependent epilepsy (PDE) caused by antiquitin (ATQ) deficiency. METHODS: In this observational study, seven children with confirmed ATQ deficiency were started on dietary lysine restriction with regular nutritional monitoring. Biochemical outcomes were evaluated using pipecolic acid and α-aminoadipic semialdehyde (AASA) levels in body fluids; developmental/cognitive outcomes were evaluated using age-appropriate tests and parental observations. RESULTS: Lysine restriction was well tolerated with good compliance; no adverse events were reported. Reduction in biomarker levels (measurement of the last value before and first value after initiation of dietary lysine restriction) ranged from 20 to 67% for plasma pipecolic acid, 13 to 72% for urinary AASA, 45% for plasma AASA and 42% for plasma P6C. For the 1 patient in whom data were available and who showed clinical deterioration upon interruption of diet, cerebrospinal fluid levels decreased by 87.2% for pipecolic acid and 81.7% for AASA. Improvement in age-appropriate skills was observed in 4 out of 5 patients showing pre-diet delays, and seizure control was maintained or improved in 6 out 7 children. CONCLUSIONS: This observational study provides Level 4 evidence that lysine restriction is well tolerated with significant decrease of potentially neurotoxic biomarkers in different body compartments, and with the potential to improve developmental outcomes in children with PDE caused by ATQ deficiency. To generate a strong level of evidence before this potentially burdensome dietary therapy becomes the mainstay treatment, we have established: an international PDE consortium to conduct future studies with an all-inclusive integrated study design; a website containing up-to-date information on PDE; a methodological toolbox; and an online registry to facilitate the participation of interested physicians, scientists, and families in PDE research.
OBJECTIVE: To evaluate the efficacy and safety of dietary lysine restriction as an adjunct to pyridoxine therapy on biochemical parameters, seizure control, and developmental/cognitive outcomes in children with pyridoxine-dependent epilepsy (PDE) caused by antiquitin (ATQ) deficiency. METHODS: In this observational study, seven children with confirmed ATQ deficiency were started on dietary lysine restriction with regular nutritional monitoring. Biochemical outcomes were evaluated using pipecolic acid and α-aminoadipic semialdehyde (AASA) levels in body fluids; developmental/cognitive outcomes were evaluated using age-appropriate tests and parental observations. RESULTS:Lysine restriction was well tolerated with good compliance; no adverse events were reported. Reduction in biomarker levels (measurement of the last value before and first value after initiation of dietary lysine restriction) ranged from 20 to 67% for plasma pipecolic acid, 13 to 72% for urinary AASA, 45% for plasma AASA and 42% for plasma P6C. For the 1 patient in whom data were available and who showed clinical deterioration upon interruption of diet, cerebrospinal fluid levels decreased by 87.2% for pipecolic acid and 81.7% for AASA. Improvement in age-appropriate skills was observed in 4 out of 5 patients showing pre-diet delays, and seizure control was maintained or improved in 6 out 7 children. CONCLUSIONS: This observational study provides Level 4 evidence that lysine restriction is well tolerated with significant decrease of potentially neurotoxic biomarkers in different body compartments, and with the potential to improve developmental outcomes in children with PDE caused by ATQ deficiency. To generate a strong level of evidence before this potentially burdensome dietary therapy becomes the mainstay treatment, we have established: an international PDE consortium to conduct future studies with an all-inclusive integrated study design; a website containing up-to-date information on PDE; a methodological toolbox; and an online registry to facilitate the participation of interested physicians, scientists, and families in PDE research.
Authors: Laura A Jansen; Robert F Hevner; William H Roden; Si Houn Hahn; Sunhee Jung; Sidney M Gospe Journal: Ann Neurol Date: 2014-01-02 Impact factor: 10.422
Authors: Malcolm Proudfoot; Philip Jardine; Agne Straukiene; Rupert Noad; Andrew Parrish; Sian Ellard; Stuart Weatherby Journal: JIMD Rep Date: 2013-02-12
Authors: Amal Al Teneiji; Theodora U J Bruun; Dawn Cordeiro; Jaina Patel; Michal Inbar-Feigenberg; Shelly Weiss; Eduard Struys; Saadet Mercimek-Mahmutoglu Journal: Metab Brain Dis Date: 2016-11-23 Impact factor: 3.584
Authors: L A Tseng; L Teela; M C Janssen; L A Bok; M A A P Willemsen; R F Neuteboom; L Haverman; S M Gospe; C R Coughlin; C D M van Karnebeek Journal: Mol Genet Metab Rep Date: 2022-03-04
Authors: Udo Fh Engelke; Rianne E van Outersterp; Jona Merx; Fred Amg van Geenen; Arno van Rooij; Giel Berden; Marleen Cdg Huigen; Leo Aj Kluijtmans; Tessa Ma Peters; Hilal H Al-Shekaili; Blair R Leavitt; Erik de Vrieze; Sanne Broekman; Erwin van Wijk; Laura A Tseng; Purva Kulkarni; Floris Pjt Rutjes; Jasmin Mecinović; Eduard A Struys; Laura A Jansen; Sidney M Gospe; Saadet Mercimek-Andrews; Keith Hyland; Michèl Aap Willemsen; Levinus A Bok; Clara Dm van Karnebeek; Ron A Wevers; Thomas J Boltje; Jos Oomens; Jonathan Martens; Karlien Lm Coene Journal: J Clin Invest Date: 2021-08-02 Impact factor: 14.808
Authors: Clara D M van Karnebeek; Sylvia Stockler-Ipsiroglu; Sravan Jaggumantri; Birgit Assmann; Peter Baxter; Daniela Buhas; Levinus A Bok; Barbara Cheng; Curtis R Coughlin; Anibh M Das; Alette Giezen; Wahla Al-Hertani; Gloria Ho; Uta Meyer; Philippa Mills; Barbara Plecko; Eduard Struys; Keiko Ueda; Monique Albersen; Nanda Verhoeven; Sidney M Gospe; Renata C Gallagher; Johan K L Van Hove; Hans Hartmann Journal: JIMD Rep Date: 2014-04-19
Authors: Curtis R Coughlin; Michael A Swanson; Elaine Spector; Naomi J L Meeks; Kathryn E Kronquist; Mezhgan Aslamy; Michael F Wempe; Clara D M van Karnebeek; Sidney M Gospe; Verena G Aziz; Becky P Tsai; Hanlin Gao; Peter L Nagy; Keith Hyland; Silvy J M van Dooren; Gajja S Salomons; Johan L K Van Hove Journal: J Inherit Metab Dis Date: 2019-02-22 Impact factor: 4.982